Dawa Life Sciences
Corporate brand
UnclaimedDawa Life Sciences is a Kenyan privately owned healthcare group that manufactures and distributes generic medicines and animal-health products across sub-Saharan Africa.
Last updated August 31, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
Dawa Life Sciences is a Kenyan life-sciences group focused on pharmaceutical manufacturing, healthcare distribution, and animal health. Its operations are centered in Kenya and serve a broader sub-Saharan African market. The group’s pharmaceutical business manufactures and markets generic medicines for human use, while its animal-health division supplies products for livestock and companion animals. The group traces its development to the establishment of Medisel Kenya Limited in the mid-1990s by Dr. Raju Mohindra and Dr. Ajay Patel. Medisel initially concentrated on distributing imported pharmaceuticals. In 2004, it acquired Dawa Pharmaceuticals Limited, a Kenyan pharmaceutical manufacturer whose history reached back to the 1970s. The acquisition added local manufacturing capacity and became the basis for the group’s subsequent expansion. Dawa Pharmaceuticals had been established in 1974 and had participated in pharmaceutical manufacturing in East and Central Africa, including contract production for Beecham Pharmaceuticals, now associated with GSK. Following the 2004 acquisition, the business operated as Dawa Limited and expanded its manufacturing portfolio, regional commercial reach, and workforce. The group later invested in specialized facilities, including a beta-lactam manufacturing plant completed in 2013 and a dedicated animal-health facility completed in 2016. The pharmaceutical division produces generic medicines in dosage forms such as tablets, capsules, syrups, and suspensions. Its therapeutic coverage includes infectious diseases, cardiology, neurology, gastroenterology, and endocrinology. The business is described as offering nearly 200 generic medicines and providing more than 100 million treatments annually across 25 African markets, although the exact reporting period for those operating figures is not specified in the available reference material. Animal health is a separate operating focus. The division markets products for livestock and companion animals and operates manufacturing capabilities for liquids, sachets, boluses, premixes, and external preparations. The pharmaceutical operation is associated with Dawa Limited in Nairobi, while the animal-health operation is associated with Medisel Kenya Limited in Thika. The group also includes Medisel (K) Limited, described as the parent and flagship company and as an importer and marketer of pharmaceutical, animal-health, and surgical products. Forest Road Development Limited is identified as a related real-estate company involved in residential and commercial property development. In 2021, the businesses unified their public identity under the Dawa Life Sciences name. In 2023, the group disposed of KEL Chemicals as part of a stated strategic realignment toward its core operations. Dawa Life Sciences remains privately owned. Its stated strategic direction is to strengthen its position as a regional manufacturer and marketer while expanding its ability to meet healthcare and animal-health demand beyond Kenya.
History
Dawa Life Sciences developed from the combination of Kenyan pharmaceutical distribution and manufacturing businesses. Its founding is associated with Dr. Raju Mohindra and Dr. Ajay Patel in 1994. The group’s early operating platform was Medisel Kenya Limited, established in the mid-1990s and initially focused on distributing imported pharmaceuticals. The manufacturing side of the group has older roots. Dawa Pharmaceuticals Limited was established in 1974 and became an important pharmaceutical manufacturer in East and Central Africa. During its earlier history, the company produced medicines under contract for Beecham Pharmaceuticals, a business now associated with GSK. This background gave the group a manufacturing base in addition to its distribution capabilities. In 2004, Medisel Kenya Limited acquired Dawa Pharmaceuticals Limited. The transaction was intended to expand and strengthen pharmaceutical manufacturing in Kenya. The acquired business was subsequently known as Dawa Limited. From that point, the group expanded its portfolio of generic medicines, developed regional commercial operations, and increased its workforce. By 2021, the pharmaceutical business was reported to employ more than 450 people, compared with fewer than 50 employees in October 2004. Manufacturing investment became a major part of the group’s growth. A dedicated beta-lactam facility was constructed in 2013, adding specialized capacity for penicillin-related products. In 2016, Dawa added an animal-health manufacturing facility. That operation was designed to produce a range of formats, including liquids, sachets, boluses, premixes, and external preparations for livestock and companion animals. The group continued to upgrade its human-pharmaceutical manufacturing platform. In 2020, it undertook the Dawa 2.0 upgrade and expanded its existing general-formulation block. The pharmaceutical division now covers dosage forms including tablets, capsules, syrups, and suspensions, and focuses on therapeutic areas such as infectious diseases, cardiology, neurology, gastroenterology, and endocrinology. The group’s commercial footprint extends beyond Kenya. Its stated operations include Uganda, Rwanda, Burundi, Zambia, Malawi, Ivory Coast, the Democratic Republic of the Congo, and South Sudan. Reference material describes the pharmaceutical division as supplying nearly 200 generic medicines and delivering more than 100 million treatments each year across 25 African markets, though the underlying time frame for those figures is not provided. The corporate structure includes Dawa Limited as the anchor pharmaceutical manufacturer and marketer, Medisel (K) Limited as the parent and flagship importer and marketer of pharmaceutical, animal-health, and surgical products, and Forest Road Development Limited as a related real-estate business. In 2021, these activities were presented under the unified Dawa Life Sciences identity. In 2023, the group disposed of KEL Chemicals, describing the move as a realignment of its core business. The group remains privately owned and continues to position itself as a regional healthcare manufacturer and marketer.
- 2023
KEL Chemicals disposal
[1]Dawa Life Sciences disposed of KEL Chemicals as part of a strategic realignment of its core operations.
- 2021
Unified Dawa Life Sciences identity
[1]The group unified its identity under the Dawa Life Sciences name.
- 2020
Dawa 2.0 manufacturing upgrade
[1]The company upgraded and expanded its general-formulation manufacturing block under the Dawa 2.0 program.
- 2016
Animal-health facility constructed
[1]A dedicated facility for animal-health manufacturing was completed.
- 2013
Beta-lactam facility constructed
[1]The group constructed a dedicated beta-lactam manufacturing facility for penicillin-related products.
- 2004
Acquisition of Dawa Pharmaceuticals
[1]Medisel Kenya Limited acquired Dawa Pharmaceuticals Limited, adding pharmaceutical manufacturing capabilities to its distribution business.
- 1995
Medisel Kenya Limited established
[1]Medisel Kenya Limited was established as an importer and distributor of pharmaceutical products.
- 1994
Dawa Life Sciences origins established
[1]Dr. Raju Mohindra and Dr. Ajay Patel founded the business associated with the later Dawa Life Sciences group.
- 1974
Dawa Pharmaceuticals Limited established
[1]Dawa Pharmaceuticals Limited was established in Kenya and developed a manufacturing role in East and Central Africa, including contract production for Beecham Pharmaceuticals.
Products and positioning
A Kenyan regional healthcare manufacturer and marketer positioned around accessible generic medicines, local production capacity, and integrated human-pharmaceutical and animal-health offerings.
Human pharmaceuticals
Dawa Life Sciences Pharmaceuticals
The pharmaceutical division manufactures and distributes generic medicines for human use. Its portfolio spans infectious diseases, cardiology, neurology, gastroenterology, and endocrinology, with major dosage forms including tablets, capsules, syrups, and suspensions. Reference material describes the division as offering nearly 200 medicines and serving markets across sub-Saharan Africa.
Animal health · 2016
Dawa Life Sciences Animal Health
The animal-health division develops, manufactures, and markets products for livestock and companion animals. Its dedicated facility can produce liquids, sachets, boluses, premixes, and external preparations, supporting the group’s broader healthcare and agricultural supply activities.
Medical and surgical supplies
Surgical products
Medisel (K) Limited is described as importing and marketing surgical products alongside pharmaceutical and animal-health products. The available material does not identify specific product names or ranges.
Brand decisions
2023
Disposal of KEL ChemicalsStrategyBackground
Dawa Life Sciences reviewed its portfolio and sought to focus on its core healthcare operations.
Action taken
The group disposed of KEL Chemicals.
Aftermath
The disposal was described as a strategic realignment toward the group’s core pharmaceutical and animal-health activities. Financial terms were not disclosed in the available material.
2021
Corporate identity unificationStrategyBackground
The group operated through multiple entities spanning pharmaceutical manufacturing, distribution, animal health, and related activities.
Action taken
The businesses were unified publicly under the Dawa Life Sciences identity.
Aftermath
The unified identity positioned the pharmaceutical and animal-health divisions as parts of a single regional life-sciences group.
2020
Dawa 2.0 manufacturing upgradeGeneration changeBackground
The group sought to increase and modernize its pharmaceutical formulation capacity.
Action taken
Dawa Life Sciences upgraded and expanded its existing general-formulation block.
Aftermath
The investment expanded the group’s manufacturing platform, although specific capacity or financial outcomes are not stated in the available material.
2004
Acquisition of Dawa Pharmaceuticals LimitedM&ABackground
Medisel Kenya Limited sought to grow its distribution business and strengthen pharmaceutical manufacturing in Kenya.
Action taken
Medisel Kenya Limited acquired Dawa Pharmaceuticals Limited, later operating the pharmaceutical business as Dawa Limited.
Aftermath
The acquisition gave the group manufacturing capabilities and provided the platform for subsequent regional expansion.
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/dawa-life-sciences · Editorial policy · How profiles are compiled